BURLINGTON, Mass., May 30, 2017 /PRNewswire/ -- Decision Resources Group finds that approximately 66% of surveyed physicians in the United States and 70% in Europe (United Kingdom, France, and Germany) report high unmet need for therapies demonstrating efficacy in delaying the onset of end-stage renal disease (ESRD) among patients with diabetic nephropathy (DN). Patients with DN account for more than 50% of all new cases of kidney disease, and it remains the single most dangerous risk factor for ESRD– a condition associated with extreme morbidity, mortality, and cost. Additional significance is placed on therapies demonstrating efficacy in improving/slowing decline of glomerular filtration rate and reducing proteinuria.
Despite the high physician ratings for unmet need on these efficacy endpoints, 67% of U.S. physicians and 83% of European physicians report moderate satisfaction with the efficacy performance of currently approved therapies. This signals that physicians are satisfied with current options to control blood pressure and glucose in the first-line, yet seek therapies with disease-modifying capabilities as nephropathy progresses.
Learn more about DRG's Diabetic Nephropathy Unmet Need report here: http://bit.ly/2qBpzZw .
Other key findings from the Unmet Need report entitled Diabetic Nephropathy:
- Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor antagonists outperform loop diuretics as well as Novo Nordisk's glucagon-like peptide-1 (GLP-1) receptor agonist Victoza (liraglutide) and Boehringer Ingelheim/Eli Lilly's sodium glucose cotransporter-2 (SGLT-2) inhibitor Jardiance (empagliflozin) as current treatments for DN, according to surveyed physicians.
- Target product profile (TPP) simulations reveal the value of a strong safety profile for emerging therapies for DN. T2D patients with nephropathy face increased risks of cardiovascular events, thus, a therapy offering cardiovascular protection is expected to see strong uptake.
- An analysis comparing the stated versus derived importance of key treatment drivers, including effects on ESRD, reducing proteinuria, and blood pressure, finds that all opportunities are well defined. Physicians in the U.S. and Europe agree on the endpoints that would successfully demonstrate a product's therapeutic value among DN patients.
- In the United Kingdom, France, and Germany, surveyed physician report DN to have the greatest unmet need among other related indications. However, U.S. physicians rank unmet need for chronic kidney disease and obesity to be slightly higher than DN. This likely reflects the different medical needs and disease prevalence between the two populations.
Comments from Decision Resources Group Analyst Caitlin Koris:
- "The emerging therapies, assuming approval, will be launching into a highly generic market in which physicians report some satisfaction with their current treatment options. In order to succeed, the drugs will need to demonstrate strong nephroprotective effects in their phase III trials – or demonstrate enhanced safety."
- "The first emerging therapy to receive an FDA approved indication in DN will represent the first disease-modifying therapy for patients with kidney disease."
Caitlin Koris has written a blog on the subject, which can be found here: http://bit.ly/2qBtRQO .
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1,000 employees across 17 global locations. DRG provides the pharmaceutical, biotech, medical device, financial services and payer industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace. www.decisionresourcesgroup.com
Decision Resources Group
SOURCE Decision Resources Group